What does “EGFR 101 to 49 in 6 months” suggest in a person taking nivolumab?
An estimated glomerular filtration rate (eGFR) drop from about 101 to 49 over 6 months indicates a substantial decline in kidney function. If this change occurred while on nivolumab, it raises concern for an immune-related kidney injury (commonly called immune-related nephritis/acute interstitial nephritis), although other causes can also produce a similar drop.
Nivolumab is an immune checkpoint inhibitor that can, in some patients, trigger inflammation in organs including the kidneys. Immune-related nephritis is a known risk with checkpoint inhibitors; the typical clinical approach is to evaluate for it when kidney function worsens during treatment.
Could nivolumab cause that much of a creatinine/eGFR change?
Yes. With kidney immune-related adverse events, eGFR (and/or creatinine) can worsen over weeks to months. A move to an eGFR around 49 generally corresponds to at least a moderate reduction in kidney function (often described clinically as stage 3 chronic kidney disease range), depending on whether the change persists after the acute trigger resolves.
The key clinical question is whether the decline is:
- ongoing and progressive,
- reversible after holding nivolumab and treating inflammation, or
- part of another process (dehydration, obstruction, infection, drug-related kidney injury from other medicines, contrast dye, uncontrolled diabetes or hypertension, etc.).
What symptoms or lab pattern would clinicians look for?
To assess whether the eGFR drop is from immune-related nephritis, clinicians typically check more than just eGFR, such as:
- Urinalysis for blood/protein and possible “active sediment”
- Urine protein quantification (protein/albumin-to-creatinine ratio)
- Urine microscopy
- Kidney ultrasound if obstruction is a concern
- A review of all medications started or changed recently (including NSAIDs, PPIs, antibiotics, diuretics, contrast imaging)
If immune-related nephritis is suspected, the pattern can include elevated creatinine with or without urinary abnormalities; imaging often helps rule out obstruction.
What actions are usually taken if eGFR drops during nivolumab?
In practice, management usually follows the severity of the kidney injury and whether other causes are excluded. Common steps include:
- Repeat kidney labs quickly to confirm trend
- Hold nivolumab temporarily if immune-related kidney injury is suspected and kidney function is significantly reduced
- Start corticosteroids for suspected immune-related nephritis if criteria are met (the exact dosing depends on severity and guidance)
- Monitor response with frequent creatinine/eGFR checks
Because guidance depends heavily on the degree of creatinine rise and persistence, exact thresholds matter and require the treating team’s data.
Could the eGFR drop be unrelated to nivolumab?
Yes. Even with cancer treatment, eGFR can fall from many causes that need separate evaluation:
- Dehydration or poor intake
- Sepsis or infection
- Urinary obstruction
- Contrast exposure (CT scans)
- Medication nephrotoxicity (for example, NSAIDs)
- Uncontrolled blood pressure, diabetes, or other chronic kidney disease progression
That’s why clinicians typically confirm the timing and rule out non-immune causes before attributing it to nivolumab.
When should someone seek urgent care?
If any of the following are present, kidney injury needs prompt medical attention:
- markedly reduced urine output
- severe weakness, confusion
- shortness of breath or swelling with rapid weight gain
- severe flank pain (possible obstruction)
- very high potassium symptoms (often detected on labs)
What I need from you to answer more precisely
“EGFR 101 to 49 in 6 months” can mean different things depending on the context. If you share these details, I can translate the situation more accurately:
1) The exact timing of nivolumab doses and when the kidney decline was first noticed
2) Latest creatinine value and whether it rose steadily or in steps
3) Urinalysis results (protein, blood) if available
4) Other kidney-affecting drugs used during the same period
5) Cancer type and whether any other immunotherapies/targeted drugs were given
Sources
No reliable source details about “nivolumab and eGFR from 101 to 49 in 6 months” were provided in your prompt, so I can’t cite specific evidence from the needed materials.